Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.11 -0.35 (-0.71%)
Official Closing Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,147,019
Open 49.41
Bid (Size) 49.42 (100)
Ask (Size) 49.57 (200)
Prev. Close 49.46
Today's Range 48.56 - 49.51
52wk Range 45.05 - 112.52
Shares Outstanding N/A
Dividend Yield 4.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets
Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million. 
Via Stocktwits
Topics Earnings
Hims & Hers Health (HIMS) Surges After Hours on Robust Q3 and Renewed Novo Nordisk (NVO) Wegovy Talks
Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of... 
Via MarketMinute
Topics Artificial Intelligence Economy

Performance

YTD
-43.9%
-43.9%
1 Month
-17.7%
-17.7%
3 Month
+0.6%
+0.6%
6 Month
-28.9%
-28.9%
1 Year
-55.2%
-55.2%

More News

Read More
Hims Says It's Negotiating A New Deal With Novo Nordisk; Shares Surge
Via Investor's Business Daily
The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit
Via Stocktwits
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera
Via Stocktwits
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer
Via Stocktwits
Hims & Hers Stock Pops After Q3 Earnings: Here's Why
Via Benzinga
Did Novo Nordisk Just Say "Checkmate" to Pfizer?
Via The Motley Fool
Topics Intellectual Property
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo
Via Investor's Business Daily
Topics Economy Lawsuit
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle
Via Benzinga
Topics Lawsuit
2 Beaten-Down Stocks That Could Be About to Rally
Via The Motley Fool
Novo Nordisk A/S (NYSE:NVO): A Top Dividend Stock with Strong Profitability and Financial Health
Via Chartmill
Should You Buy Viking Therapeutics Before Nov. 5?
Via The Motley Fool
Is It Time to Dump Your Shares of Pfizer?
Via The Motley Fool
Topics Intellectual Property
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal
Via Investor's Business Daily
Topics Law Enforcement Lawsuit
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise
Via Stocktwits
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
Via Benzinga
Topics ETFs
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
Via Investor's Business Daily
Topics Economy Government
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Via Benzinga
1 Incredible Reason to Buy Novo Nordisk Stock (NVO) in November -- or Sooner
Via The Motley Fool
Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried?
Via The Motley Fool
Topics Government Intellectual Property
If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These
Via The Motley Fool
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 49.11
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 11/03/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.